Overview

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, phase II/III clinical study to evaluate the efficacy and safety of SSD8432 in combination with ritonavir in adult subjects with mild/common COVID-19.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Treatments:
Ritonavir